annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 51A Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in
combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical
models of osteosarcoma (OS). (Abstract #10058)
Y. Pignochino, G. Grignani, M. Basiricò, G. Cavalloni, M. Motta, S. Bruno,
S. Aliberti, M. Alberghini, P. Picci, M. Aglietta
Brd. 51B Sunitinib (SU)-related hypertension in a randomized placebo (P)-controlled
trial of GIST patients (pts). (Abstract #10059)
M. Ewer, T. M. Suter, D. J. Lenihan, L. Niculescu, A. Breazna, R. J. Motzer,
G. D. Demetri
Brd. 51C A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma
(CS) expressing platelet-derived growth factor receptor-� or -�; (PDGFR-�/
PDGFR-�): An Italian Sarcoma Group study. (Abstract #10060)
G. Grignani, E. Palmerini, S. Stacchiotti, A. Boglione, V. Ferraresi, S. Frustaci,
A. Comandone, P. G. Casali, S. Ferrari, M. Aglietta
Brd. 51D Adjuvant imatinib therapy of 208 gastrointestinal stromal tumor (GIST)
patients: Dose, duration, and risk assessment. (Abstract #10061)
J. C. Trent, M. von Mehren, P. W. Pisters, E. Stealey, L. A. Sirulnik, C. D. Blanke
Brd. 51E Quality of life (QoL) in osteosarcoma: First results of the presurgery
treatment period of EURAMOS-1 (NCT00134030). (Abstract #10062)
A. Wiener, R. Nagarajan, L. Hjorth, M. Jenney, P. De Vos, M. L. Bernstein,
M. D. Krailo, M. R. Sydes, G. Calaminus, for the EURAMOS-1 Study Group
Brd. 51F High-dose photon-beam radiation therapy in chordoma: A single-institution
retrospective analysis. (Abstract #10063)
C. Sangalli, S. Stacchiotti, A. Gronchi, P. G. Casali, E. Pignoli, P. Pittoni,
E. Palassini, P. Olmi
Brd. 51G Impact of imatinib plus best supportive care in imatinib- and sunitinibexposed
patients with refractory advanced gastrointestinal stromal tumor.
(Abstract #10064)
A. Sawaki, T. Kanda, Y. Komatsu, T. Nishida
Brd. 51H Metronomic oral cyclophosphamide (CPM) and prednisolone in elderly
patients (pts) with inoperable or metastatic soft tissue sarcoma (STS).
(Abstract #10065)
O. Mir, J. Domont, A. Cioffi, S. Bonvalot, B. Boulet, C. le Pechoux, G. Missenard,
F. Rimareix, P. Terrier, A. Le Cesne
Brd. 52A PAX3/7-FOXO1 fusions by fluorescent in situ hybridization (FISH) using an
adult rhabdomyosarcoma tissue microarray. (Abstract #10066)
S. N. Dumont, A. J. Lazar, J. A. Bridge, J. C. Trent
Brd. 52B Cutaneous angiosarcoma of the head and neck. (Abstract #10067)
P. K. Pandalai, J. L. Hornick, Q. Wang, J. A. Morgan, S. George, E. H. Baldini,
P. M. Devlin, C. P. Raut
Brd. 52C Quality of surgical margins and local recurrence in primary extremity soft
tissue sarcoma (STS). (Abstract #10068)
S. Bonvalot, A. Dunant, C. le Pechoux, P. Terrier, F. Rimareix, B. Boulet,
L. Medjoub, A. Cioffi, J. Domont, A. Le Cesne
Brd. 52D Immunohistochemical study and fluorescent in situ hybridization analysis of
JAZF1 in 67 cases of endometrial stromal tumors collected in a tissue
microarray. (Abstract #10069)
J. Duclos, A. Valent, G. Malouf, F. Drusch, N. Auger, P. Vielh, G. Vassal,
P. Duvillard, P. Pautier
Brd. 52E Prognostic factors of KIT-negative GIST-like patients (KNGL): A Spanish
Group for Sarcoma Research (GEIS) study. (Abstract #10070)
J. Martin Broto, X. Garcia del Muro, J. Rubio, A. Gutierrez, J. Martinez-Trufero,
I. Sevilla, N. Lainez, R. Andres, R. Ramos, J. A. Lopez-Guerrero
282